Veea Inc. provider of AI-powered, cybersecure edge infrastructure, and NovaGen Group B.V., personalized regenerative medicine and longevity company, today announced they have signed term sheet to combine and are targeting execution of definitive business combination agreement within coming weeks. In connection with business combination, parties have also announced agreement to launch NovaGen Health Networks: connected health platform integrating Veea's edge computing, connectivity and cybersecurity capabilities with NovaGen's cellular reprogramming science and clinical services. Initial deployments will begin at NovaGen clinics and partner hospitals in Q4 2026.
Proposed combination seeks to establish Nasdaq-listed longevity and precision-health platform, complementing Veea's continuing edge AI infrastructure business; GeoNova Capital commits US$10 million as cornerstone institutional investor.
Platform, built on VeeaONE, connects health records, wearable and sensor data, and biological measurements into patient-controlled longitudinal health profile. Local computing supports agentic AI applications close to patient, with patient-directed permissions governing access to personal data.
Companies plan to roll out NovaGen Health Networks in two phases. Phase 1 Connecting People, Data and Care Q4 2026 will provide private household health hub with digital twin for every family member and patient-controlled health records wallet, integrating health records, wearable telemetry and longitudinal biological measurements. Built on VeeaONE, hub processes sensitive data locally and supports AI wellness companions, medication reminders, and patient-authorized provider sharing.
Phase 2 Clinician-Supervised Diagnostics and Therapy Pathways as clinical validation and regulatory authorizations permit, network will combine digital twins and medical records with cellular data from small skin biopsy used to initiate ARC Prometheus process. Biopsy provides patient's own fibroblasts for cellular reprogramming, rejuvenation, cell banking and potential future autologous therapies. Telomere length, DNA-methylation age and additional biomarkers will be assessed to support clinician evaluation.
"NovaGen is regenerative medicine platform with proprietary autologous rejuvenated fibroblast stem cell technology and growing network of associated clinics. This agreement with Veea extends our reach to individuals long before they walk into clinic," said Diederik van der Reijt, CEO of NovaGen Group. "NovaGen Health Networks creates pathway to identify and evaluate potential candidates for our therapies."
"NovaGen Health Networks demonstrates power of AI at edge, bringing Veea's connectivity, computing, cybersecurity, storage and AI capabilities together in one global network, putting intelligence where care happens while giving people far greater control over their most personal information," said Allen Salmasi, Chairman and CEO of Veea.
Data Sovereignty and Privacy central to network design. Health records remain encrypted at source and off blockchain; blockchain ledger records only permissions, document fingerprints and access events. Patients authorize specific recipients, categories of information and access periods, and may revoke access at any time. Cloud services use pseudonymous digital twins, with re-identification controlled through protected keys and authorized consent. Veea's cybersecurity architecture, incorporating Zero Trust Network Access, network slicing, micro-segmentation and AI-driven anomaly detection, protects network end-to-end.
About Veea
Veea Inc. is global leader in edge solutions and infrastructure. Founded 2014 headquartered New York City, Veea enables enterprises, service providers and public sector organizations to deploy AI-powered applications at edge. VeeaONE platform integrates connectivity, computing, cybersecurity and storage.
About NovaGen Group
NovaGen Group has developed personalized regenerative medicine and longevity platform integrating ARC Prometheus cellular reprogramming and rejuvenation technology, biological assessment, cell banking, clinical services and digital health.
About GeoNova Capital
GeoNova Capital is UAE-based investment and capital-markets firm focused on event-driven investing, structured finance, special situations and public-market transactions.
